Clinical Competition Candidate
EMEND
EMEND carries product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 15 months away. Active clinical competition may compress the generic entry window.
LOE window
15months
to latest listed patent expiry (September 26, 2027)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 2
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 233
Phase 2/3 trials: 122
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: APREPITANT
Applicant (NDA holder): MERCK SHARP AND DOHME LLC
Confidence: High